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Abstract
Lack of adequate human resource capacity, good governance, sound physical infrastructure and well-functioning
systems impede economic growth in low- and middle-income countries. The heavy burden from disease com-
pounds this. To overcome these setbacks a concerted effort needs to be taken. This requires collective effort of all
including the public and private sectors from development partners and from low- and medium-income countries
themselves. Specific research capacity gaps, such as lack of expertise and infrastructure to engage in upstream
research and development of new products, need to be addressed. Special attention should also be given to those
with more acute capacity needs and high disease burden, such as communities in conflict-affected regions.
Capacity building approaches need to be innovative and responsive to needs and the ever changing scientific
landscape. Therefore, for example, as the global community aims to eliminate and eventually eradicate malaria,
there should be an appropriately matched effort to strengthen the capacity to meet these challenges.
Background
Capacity development is the process of enabling indivi-
duals or systems to recognize and solve their own pro-
blems, make informed choices, define priorities and plan
their futures in a sustainable manner. This effort may be
targeted to specific individuals, institutions, organiza-
tions, communities or entire nations. Similarly it may be
targeted to specific tasks and needs or in broad terms at
the overall strengthening of systems.
Traditionally, most of the efforts on capacity develop-
ment in the past have been targeted at individuals,
mostly through training. The training may be conducted
in the form of workshops, seminars, short- and long-
term professional courses or mentoring. However, this
may not always be effective since such a trained indivi-
dual without appropriate supporting structures and
enabling environment may not be able to function opti-
mally. A more effective, but not necessarily well-appre-
ciated form of capacity strengthening is at institutional
level, whereby efforts are targeted to strengthening
policies, governance and programmes. Delivered in this
manner, capacity development may not only be aligned
to the existing programmes and policies, but also built
along the existing supporting structures thus ensuring
utilization and sustainability of the strengthened
capacity.
A higher level of capacity strengthening is that of
national or regional support. Such societal capacity
building may involve national policies, governance, laws
and regulations. This has in the past generally been very
much neglected by many international development
partners in favour of projects support. This omission is
particularly in the area of research for health, which
continues to be neglected, especially within the current
favoured approach of general budget support to low-
and middle-income countries. Although it may be politi-
cally correct to channel aid through general budget
support and sector wide approach, quite often such sup-
port does not adequately reach health research sector
due to many other competing needs. Moreover, there is
no evidence to support that such approaches are effec-
tive and have a real impact in powering capacities [1]. Correspondence: Mgone@edctp.org
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leadership
Strengthening of the research capacity for malaria must
be holistic and viewed as part of the big picture in the
development of capacity for research for health, which
will in turn contribute to improving community health
in general. Primarily, it is the responsibility of every
nation to ensure that it can provide the best services
including healthcare to its people. This will include hav-
ing the required capacity in terms of personnel and
infrastructure. Unfortunately, this is not often possible
in most of the low- and middle-income countries, where
due to lack of economic empowerment capacity devel-
opment mostly depends on foreign aid. Unfortunately,
left this way low- and middle-income countries will
have no control in addressing to their capacity needs.
For capacity development to be effective, the process
must be owned and driven by those who need the capa-
city and tailored to response to their needs. Ownership
requires active involvement including participation in
decision making on the required capacity, investing on
the capacity development processes as well as the utili-
zation and retention of the developed capacity. Unfortu-
nately, more often this is not the case as most of the
low-income countries, especially in sub-Saharan Africa,
grossly under-invest in health research, particularly on
capacity development and depend on foreign aid. In
many countries this aid may comprise more than 90%
of the health research budget [2]. This unfortunately
precludes researchers and policy makers from owning
and driving their own national research agenda accord-
ing to their needs and wishes. Moreover, this situation
is neither uniform nor being equally addressed in all
countries; with some more acutely affected than others.
For example, within sub-Saharan Africa there is a great
disparity in both local investment on health and in
receiving foreign aid for health, often with conflict-
affected fragile states that need more support getting the
least [3]. This is a paradox, since it is well known that,
because of their inadequate capacities, low and medium
conflict-affected countries not only rely heavily on inter-
national aid [4], but also have worse development
indicators compared to their non-conflict affected coun-
terparts [4,5].
Many developing countries generally lack broad-based
research and scientific leadership to compete for
research grants to initiate and manage research projects.
Such lack of capacity greatly handicaps scientists from
these regions to be in driving seats and own research
programmes. This is a great disadvantage since it pre-
vents those in malaria-endemic countries to truly set the
agenda and help them solve their own problems. To be
competitive, researchers from developing countries
require capacity support in project writing, grant
application and research project management skills.
This should include training of the supporting staff in
contract negotiations and in intellectual property rights
management. Very often than not researchers and
research managers in developing countries relinquish
this to their collaborators in the north.
Product discovery and early phase research &
development
Another notable capacity deficiency in most low- and
middle-income countries is lack of ability to participate
in product discovery and early research and develop-
ment. This includes basic research to discover new med-
icinal and biological compounds such as diagnostics,
drugs and vaccines. Invariably most of all the current
early drug and vaccine development prior to the first in
man development phases (including those for malaria)
takes place in the north. This stems from lack of per-
sonnel, sound regulatory framework and appropriate
infrastructure including laboratory and good manufac-
turing practice facilities. Ironically, it is the same lack of
such basic framework that undermines the development
of the capacity that would free low-income countries
from this situation. The lack of capacity to take part in
early research and development of new products also
translates into lack of pharmaceutical manufacturing
facilities. It is hoped that the recently launched African
Network for Drugs and Diagnostics Innovation (ANDI)
whose mission is to promote sustainable product inno-
vation to address African needs will mitigate this defi-
ciency and stimulate drug discovery and development in
sub-Saharan Africa. ANDI aims to achieve this by estab-
lishing and coordinating the formation of collaborative
projects of African networks for research and develop-
ment from product discovery to manufacturing includ-
ing supporting capacity building. This will include
providing support through direct funding, infrastructure
strengthening, advocacy and fostering of public-private
partnerships [6].
The dearth of capacity and activities in drug discovery
and early development in developing countries is a mir-
rored in vaccine development. For example, the current
norm in the malaria vaccine research and development
pathway is to conduct all initial studies including first in
man safety and immunogenicity studies (phase Ia clini-
cal trials) in the north. This also applies for challenge
model studies (phase IIa), which are now generally
becoming a prerequisite for down selection of candidate
vaccines to help in accelerating their development. The
current costly and time consuming approach of con-
ducting initial clinical trials in developed countries prior
to moving on to endemic countries is partly due to lack
of infrastructure, personnel and regulatory capacity to
conduct and oversee such studies in endemic countries.
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malaria vaccine, it has been suggested that these earlier
studies should also be conducted in malaria-endemic
countries [7]. To overcome these constraints there is a
need to strengthen broad reaching capacities including
molecular biology, immunology and parasitology labora-
tory facilities, state of the art mosquito insectaries and
competent ethical and regulatory framework.
There are also some important capacity gaps in the
downstream end of research and development of pro-
ducts. These include project management and govern-
ance skills; data management including its ownership
and utilization; and processing of vital laboratory assays.
However, lack of capacity often relegates institutions
from endemic countries that participate in multicentre
studies to play peripheral roles, such as sample collec-
tion and processing, conducting of marginal laboratory
tests and shipping samples abroad for more the more
vital tests. These capacity gaps can however, be tacked
with targeted capacity building. A good model that
addresses this issue in malaria vaccine evaluation is the
Afro-Immuno Assay (AIA) network. The network com-
prising of institutions from Burkina Faso, Gabon,
Ghana, Senegal, Tanzania and Zimbabwe in partnership
with Denmark, Netherlands and France has developed
standardized enzyme immunoassays, that ensure use of
same reagents, protocols and statistical methods in the
evaluation candidate malaria vaccines [8]. These include
assays for the Glutamate-rich Protein (GLURP), the
Merozoite Surface Protein 3 (MSP3), the 19-kilo Dalton
region of the Merozoite Protein 1 (MSP119)a n dt h e
Apical Membrane Antigen 1 (AMA1), which are among
the current malaria vaccine development pipeline [8-11].
This network uses standardized protocols, common pool
and sourcing of reagents, harmonized project manage-
ment and centralized quality assurance and governance.
The network also facilitates south-south mentoring, staff
exchange and creation of a critical mass of scientists
working together for a common goal. Such programmes
that are owned and led by scientists from developing
countries must be encouraged and emulated.
Malaria control, elimination and eradication
Since the announcement by Bill & Melinda Gate Foun-
dation that malaria eradication is one of their goals [12]
and the endorsement of the World Health Organization
(WHO) and the Roll Back Malaria (RBM) Partnership
on the elimination of malaria in countries where this is
possible, there has been a rekindled interest in malaria
control and elimination programmes. It is generally
agreed that even with the currently available tools,
national or regional elimination of malaria is probably
possible, especially where malaria endemicity is low
[13,14]. However, in areas of high transmission regions
this will require increased efforts such as scaling up of
interventions and use of innovative control measures.
This may include progressive containment starting with
elimination in countries bordering high transmission
areas and gradually moving to eliminate the disease in
high endemic regions [15]. However, for this to be
achieved human resource and infrastructure capacity
with require to be strengthened. Skills and empower-
ment in data analysis, modelling and decision making
will have to be improved and proliferated to support
innovative control methods.
One of the innovative ways of strengthening malaria
control and elimination is by the integrated vector man-
agement control. This comprises use of evidence-based
decision-making; integration of different control mea-
sures; sector-wide collaboration within and outside the
health sector; advocacy, social mobilization and legisla-
tion; and capacity strengthening to manage such pro-
grammes. Such capacity building should include the
enabling of appropriate utilization of data in decision-
making, and evaluation of the currently ongoing vector
control programmes, such as use of insecticide-treated
bed nets and indoor residual spraying; employment of
additional vector control tools and other interventions
such as case detection and treatment strategies; moni-
toring and evaluation of these strategies; and a contin-
ued global search and evaluation of new tools [16]. This
will also require the development of essential physical
infrastructure, financial resources and human capacity,
at both local and national levels. One of the success
stories emanating from this approach is that of the
Zambia National Malaria Control Programme, which
has expanded its vector control coverage and leveraged
resources to develop a national capacity that has greatly
improved malaria control in the country [17]. Similar
success has been reported elsewhere in Africa [18]. It is
therefore now very important as we come towards the
“end game” and push for global and comprehensive
malaria control, elimination and eventual eradication,
due attention must be paid to the strengthening of the
necessary capacity that is required to realize this impor-
tant goal.
Innovative ways of capacity development
In order to address some of these issues, it is encoura-
ging to note that in recent times several international
development partners and research funders have been
adopting different innovative mechanisms for supporting
capacity development. For instance in response to the
regional disparity in capacity for health research and
investment in health research in sub-Saharan Africa, the
European & Developing Countries Clinical Trials part-
nership (EDCTP) has launched Regional Networks of
Excellence for conducting clinical trials [19,20]. This
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institutions of different strengths and weaknesses to col-
laborate in conducting clinical trials and research while
supporting each other taking advantage of their
strengths. This regional approach and partnering of
institutions of varying strength, mitigates the negative
effects of the traditional tendencies of supporting stron-
ger institutions at the expense of the weaker ones.
Other examples of innovative approaches towards capa-
city development include the Wellcome Trust African
Institutions Initiative [21] and the recently launched
Medical Research Council/ United Kingdom’sD e p a r t -
ment for International Development (MRC/DfID) Afri-
can Research Leadership Scheme. It is also very
encouraging to note that many of these schemes have
partnerships as the foundation of their programmes
[19-23] and indeed some such as the EDCTP pro-
gramme encourage ownership and leadership from part-
ners in the south, which includes mutual decision-
making in prioritization of the research agenda and
capacity building activities [19,20,22]. However, if any of
these measures are to be effective and sustainable they
will require local commitment, ownership and invest-
ment. Thus, effective capacity building must be a shared
responsibility that requires proactive involvement of
both international development partners and partners
from the south including from private sector. Since it is
the developing countries that are going to benefit most
from the developed capacity in their nations, it is appro-
priate that they should put more effort in building that
capacity. This calls for a specific efforts to determine
what is required and make appropriate investments
including nurturing of a conducive environment to uti-
lize, retain and. sustain such capacity. It must however,
be emphasized that this should always be accepted to be
long-term endeavour, rather than a quick-fix adventure.
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